Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

Most bronchiectasis patients experience loss of lung function over time due to the irreversible damage caused by the progressive disease. But in this large, international, randomized ASPEN trial ...

A total of 1,680 adults and 41 adolescents were randomly assigned to brensocatib or placebo. The researchers found that the annualized rate of pulmonary exacerbations was 1.02, 1.04, and 1.29 in ...

Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis. The phase 3 trial ...

Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine , 2025; 392 (16): 1569 DOI: 10.1056/NEJMoa2411664 Cite This Page : ...